← Back

Clinical Medicine and Surgery I · Exam 6 — Clin Med Pro Guide

PAJ 5500 Clinical Medicine and Surgery I · Class of 2028

Respiratory I block · 22 conditions across 6 lectures · Dr. Carter’s Clin Med Pro Study Tip, ten fields per condition

How to use this guide

Dr. Carter’s Clin Med Pro Study Tip (Hypotension deck, slide 7) lists what to learn for every condition. Each card below answers those ten fields:

  1. Name of Condition
  2. Definition
  3. Etiology (cause)
  4. Epidemiology (who)
  5. Risk Factors
  6. Pathology
  7. Clinical Manifestation
  8. Diagnosis
  9. Treatment/Therapy
  10. Mortality ★

Every field comes from the lecture slides only. Where a deck is silent the card says Not covered in the lecture rather than filling the gap from elsewhere (25 of 220 fields in this exam; Mortality alone: 14 of 22). Slide numbers follow each field. Cards open closed; tap one to read it.

The ★ on Mortality is on the original study-tip slide: fill it when a figure exists. A ★ highlighted phrase inside a field is a fact the professor emphasized in the lecture recording, carried over from this exam’s study guide.

Lecture 33 · Oxygen Delivery

Lauren Reynolds, MSPA, PA-C · 0 conditions · source: 35. Oxygen Delivery 2026.pptx

Note: Oxygen delivery is a therapy lecture, not a disease lecture, so it has no condition cards: its indications, devices, home oxygen qualification and safety teaching are in section 1 of the Exam 6 study guide and on the cram sheet. The deck file is numbered 35; the calendar calls it Lecture 33.

Lecture 34 · Acid-Base Part I

Megan B. Finck, MMS, PA-C · 4 conditions · source: PAJ5500 CMSI Acid Base MBF 2026sc.pptx

Note: Built from the slides plus the lecture recording: the recording only chooses which facts to star, it adds no content. The four simple disorders are the conditions. The slides give no incidence or mortality figures; the only outcome stated is the unsustainable pH (below 6.7 or above 7.6), kept as the slide prints it. The board cases at the end of the lecture are not in the deck and are not used.
Respiratory acidosis★ Professor emphasized2 not covered

★ Chronic obstructive pulmonary disease is the first cause to think of; the sleepy, confused patient; acute versus chronic is read from how far the kidneys have compensated; the obesity hypoventilation syndrome triad is a frequent question.

Name of Condition
Respiratory acidosis (acute or chronic) Slide 21
Definition
Hypoventilation raising the partial pressure of carbon dioxide (greater than 40 mm Hg) and causing acidemia (pH below 7.35); may be accompanied by hypoxemia; may be acute or chronic Slide 21
Etiology (cause)
Acute: airway obstruction; pulmonary disease (pneumonia, asthma, pulmonary edema, aspiration pneumonitis); central nervous system depression (recreational drugs, intracranial catastrophe, intravenous sedation); neuromuscular disorders (myasthenia gravis, Guillain-Barré syndrome); thoracic trauma (pneumothorax, flail chest). Chronic: lung disease (★ chronic obstructive pulmonary disease, interstitial lung disease, idiopathic pulmonary fibrosis); neuromuscular disorders (muscular dystrophy, amyotrophic lateral sclerosis); obesity hypoventilation syndrome Slides 26–27
Epidemiology (who)
Not covered in the lecture
Risk Factors
★ Obesity hypoventilation syndrome (Pickwickian syndrome): the triad of obesity, sleep disordered breathing and chronic hypercapnia Slide 27
Pathology
Hypercapnia is usually from under-excretion (hypoventilation), not excess production. Compensation is renal: the kidneys excrete acid as ammonium chloride and retain bicarbonate, beginning 6 to 12 hours after onset; complete compensation may take days. Bicarbonate rises about 1 mEq/L per 10 mm Hg rise in carbon dioxide acutely and about 3.5 chronically Slides 14, 22, 59
Clinical Manifestation
Somnolence, confusion, altered mental status, asterixis, myoclonus. Severe hypercapnia: increased cerebral blood flow, intracranial pressure and cerebrospinal fluid pressure; papilledema may be seen Slides 23–24
Diagnosis
Low arterial pH, increased carbon dioxide, elevated serum bicarbonate; hypochloremia with chronic acidosis (renal excretion of acid as ammonium chloride). Respiratory disorder: compare the bicarbonate with its expected level to judge acute versus chronic Slides 25, 61
Treatment/Therapy
Treat the underlying cause. Acute: restore ventilation. Chronic: careful oxygen titration; avoid rapid or aggressive carbon dioxide reduction, which causes posthypercapnic metabolic alkalosis Slide 28
Mortality ★
Not covered in the lecture
Respiratory alkalosis★ Professor emphasized3 not covered

★ The paper bag "doesn't actually do anything": it is not necessary, does not correct carbon dioxide, may lower oxygen and works as a placebo.

Name of Condition
Respiratory alkalosis (acute or chronic) Slide 29
Definition
Hyperventilation lowering the partial pressure of carbon dioxide and causing alkalemia (pH above 7.45) Slide 29
Etiology (cause)
Central hyperventilation (voluntary or psychogenic, cerebrovascular accident, increased intracranial pressure); hyperventilation from hypoxia (high altitude, severe anemia, ventilation-perfusion mismatch, hypotension); toxic or pharmacologic (salicylates, caffeine, nicotine, catecholamines, thyroxine); pulmonary (pulmonary embolism, pneumonia, pulmonary edema, mechanical hyperventilation, interstitial lung disease); endocrine (pregnancy, hyperthyroidism); septicemia; heat exposure; hepatic failure Slides 33–34
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
Hypocapnia is usually from excess excretion (hyperventilation). Initial compensation: cells secrete hydrogen ions in exchange for potassium. Then the kidneys excrete bicarbonate and retain chloride, giving a reduced bicarbonate, hypokalemia and hyperchloremia. Bicarbonate falls about 2 mEq/L per 10 mm Hg fall in carbon dioxide acutely and about 5 chronically Slides 14, 30, 59
Clinical Manifestation
Light-headedness, anxiety, perioral numbness, paresthesias; in severe cases tetany from low calcium, because a high pH increases calcium binding with albumin Slide 31
Diagnosis
Elevated arterial pH, low carbon dioxide; decreased bicarbonate in chronic respiratory alkalosis Slide 32
Treatment/Therapy
Treat the underlying cause; hyperventilation is usually self-limited. ★ Breathing into a paper bag is not necessary: it does not correct carbon dioxide, may decrease oxygen, and works as a placebo. Rapid correction of chronic respiratory alkalosis may cause posthypocapnia metabolic acidosis Slide 35
Mortality ★
Not covered in the lecture
Metabolic alkalosis★ Professor emphasized2 not covered

★ Saline responsive is the common type; compensation rarely takes carbon dioxide above 55 mm Hg; urine chloride splits the two types and blood pressure then sorts the saline-unresponsive causes; licorice is "a unicorn".

Name of Condition
Metabolic alkalosis (saline responsive or saline unresponsive) Slide 36
Definition
Elevated serum bicarbonate causing alkalemia. Two types: saline responsive (a sign of extracellular volume contraction) and saline unresponsive (elevated bicarbonate with euvolemia or hypervolemia) Slides 36–37
Etiology (cause)
Saline responsive: diuretic therapy, posthypercapnia, loss of hydrochloric acid (vomiting, nasogastric suction), antacids, volume contraction. Saline unresponsive, normotensive: severe potassium depletion, hypoparathyroidism and hypercalcemia. Saline unresponsive, hypertensive: primary aldosteronism, exogenous alkali, mineralocorticoids, licorice Slides 42–43
Epidemiology (who)
★ Saline responsive is the more common type Slide 36
Risk Factors
Not covered in the lecture
Pathology
Compensation is decreased ventilation to retain carbon dioxide, about 0.75 mm Hg per 1 mEq/L rise in bicarbonate; ★ carbon dioxide is rarely above 55 mm Hg from compensation, so a higher value suggests a concurrent primary respiratory acidosis Slides 38, 59
Clinical Manifestation
No characteristic findings; may have orthostatic hypotension; associated hypokalemia causes weakness and hyporeflexia Slide 39
Diagnosis
Elevated arterial pH and serum bicarbonate; increased carbon dioxide with respiratory compensation; decreased potassium and chloride. ★ Urine chloride differentiates the types: lower in saline responsive (below 25 mEq/L), higher in saline unresponsive (above 40 mEq/L) Slides 40–41
Treatment/Therapy
Treat the underlying cause. If saline responsive: isotonic saline to correct the extracellular volume deficit, and discontinue diuretics if present Slide 44
Mortality ★
Not covered in the lecture
Metabolic acidosis★ Professor emphasized2 not covered

★ "By far the most complex": know the two mnemonics, and commit the Winter formula and the anion gap calculation to memory.

Name of Condition
Metabolic acidosis (normal anion gap or elevated anion gap) Slide 45
Definition
Reduced serum bicarbonate causing acidemia: acids added (intrinsic or exogenous), acid excretion impaired, or bicarbonate lost. Two types: normal anion gap and elevated anion gap Slides 45, 53
Etiology (cause)
Elevated anion gap (MUDPILES): methanol, metformin, uremia, diabetic ketoacidosis, paraldehyde, isoniazid, iron, lactic acidosis, ethylene glycol, salicylates, starvation (metabolic and drug or chemical anions). Normal anion gap (USEDCAR): ureteral diversion, saline infusion, exogenous acid, diarrhea, carbonic anhydrase inhibitors, adrenal insufficiency, renal tubular acidosis (loss of bicarbonate, chloride retention, acids) Slides 54–56
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
Increased acid production or ingestion, loss of bicarbonate, or decreased renal acid excretion. Compensation is increased ventilation to lower carbon dioxide; in severe cases hyperventilation is profound, as Kussmaul respirations (increased tidal volume and tachypnea) in diabetic ketoacidosis. The anion gap is the anions other than chloride and bicarbonate; albumin makes up most of the normal gap Slides 46, 50, 53
Clinical Manifestation
Mainly the signs and symptoms of the underlying disorder, plus compensatory hyperventilation Slide 51
Diagnosis
Decreased pH, bicarbonate and carbon dioxide; hyperkalemia may be present. ★ Anion gap = sodium - (chloride + bicarbonate), normal 9 to 15: normal gap is hyperchloremic, elevated gap is normochloremic. A normal gap does not exclude acidosis and should not override clinical concern (errors: hypoalbuminemia, hypernatremia or hyponatremia, antibiotics). ★ Winter formula: expected carbon dioxide = 1.5 x measured bicarbonate + 8, plus or minus 2; a higher measured value means an added respiratory acidosis, a possible sign of impending respiratory failure Slides 47–49, 52, 58
Treatment/Therapy
Treat the underlying disorder, for both gap types; assess the compensatory response with the Winter formula. A pH below 6.7 may warrant therapy to normalize the pH along with treatment of the cause Slides 8, 57–58
Mortality ★
A pH below 6.7 (or above 7.6) is unsustainable: it may cause cardiac hypocontractility or irritability, seizures, cerebral edema and metabolic disturbances Slide 8

Lecture 35 · Asthma

Megan B. Finck, MMS, PA-C · 2 conditions · source: PAJ5500 CMSI Asthma MBF 2026sc.pptx

Note: Built from the slides plus the lecture recording: the recording only chooses which facts to star, it adds no content. Adult content (12 and older) only; epidemiology numbers and emergency management are context, not tested. Brand names and dosing are left out. Where a slide is loose (high-dose inhaled steroid systemic effects, cromolyn filed under bronchodilators, the pneumococcal age band), the field says so or leaves it out.
Asthma★ Professor emphasized

★ Classifying severity from a patient description (most severe feature wins), the written action plan and zones, inhaler and spacer technique, and drug classes rather than brands were stressed; epidemiology and emergency care are not tested.

Name of Condition
Asthma (extrinsic and intrinsic types) Slides 5, 34–36
Definition
★ Chronic inflammatory airway disorder with reversible airflow obstruction (some long-standing cases irreversible): recurrent breathlessness and wheezing and difficulty getting air out. Airway hyper-responsiveness is excessive bronchoconstriction to a trigger a normal airway ignores Slides 5, 7–11
Etiology (cause)
Not fully understood: genetic predisposition (polygenic) plus environment. ★ Atopy (raised immunoglobulin E; atopic triad of allergic rhinitis, asthma, atopic dermatitis); obesity (body mass index above 30); early viral infection. Inhaled allergens (dust mites most common), occupational sensitizers, air pollution and passive smoke (controversial) Slides 23–33
Epidemiology (who)
Any age, peak presentation at 3 years; may go quiet in adolescence and return in adulthood. Statistics were not tested. Severity rarely changes: mild rarely becomes severe, severe is usually severe at onset Slides 12–13
Risk Factors
Atopy, family history, obesity, occupational exposure. Triggers: allergens, viral infections, aspirin and beta blockers, exercise, cold air, pollution, smoke, stress. Allergen avoidance does not reduce the risk of developing asthma. Death risk: frequent bronchodilator use, no or poorly taken inhaled corticosteroid, previous near-fatal admission Slides 14, 24–32, 37–42
Pathology
Bronchoconstriction, airway edema, vascular congestion, mucus plugging; lowers the 1-second volume, its ratio to forced vital capacity, and peak flow. Extrinsic: allergen-triggered, most common. Intrinsic (about 10%): negative skin tests, normal immunoglobulin E, adult onset, usually more severe, nasal polyps, may be aspirin sensitive. Other types: occupational, catamenial, cardiac, exercise-induced, aspirin-sensitive Slides 7–10, 34–36
Clinical Manifestation
Episodic wheeze, dyspnea, chest tightness, cough, sputum; worse at night (peak 3 to 4 in the morning); exam may be normal between exacerbations; extrinsic: swollen nasal mucosa, eczema, nasal polyps. Exacerbation: accessory muscle use, leaning forward; wheeze may disappear in a severe exacerbation Slides 45–51
Diagnosis
★ Spirometry before and after a short-acting bronchodilator: reduced 1-second volume and ratio; improvement of 12% or more supports asthma; repeat yearly. Provocation testing if nondiagnostic (not below 65% predicted); exercise challenge; allergy testing; exhaled nitric oxide. Home peak flow: 20% change = poor control. ★ Severity (12 and older): intermittent, mild, moderate, severe persistent by symptoms, nights, rescue use, activity limit and 1-second volume; most severe feature wins Slides 52–61, 69
Treatment/Therapy
Trigger avoidance; every patient needs a short-acting beta-2 agonist; ★ inhaled corticosteroid first-line for persistent asthma (spacer, rinse); long-acting beta-2 agonist only with an inhaled steroid; add-ons: leukotriene modifier, cromolyn, tiotropium, theophylline (rarely); monoclonal antibodies by specialists; short systemic steroid course for exacerbations, none long-term unless refractory. Avoid aspirin, non-selective anti-inflammatory drugs and beta blockers. Written action plan with zones; vaccines (caution with intranasal influenza); check compliance and technique first when control is poor Slides 66–96
Mortality ★
Death uncommon; declining in affluent countries with widespread use of inhaled corticosteroids. Death risk: frequent bronchodilator use, no or poorly taken inhaled corticosteroid, previous near-fatal admission Slides 13–14
Allergic bronchopulmonary aspergillosis2 not covered
Name of Condition
Allergic bronchopulmonary aspergillosis Slide 65
Definition
Hypersensitivity reaction to Aspergillus species (Aspergillus fumigatus) Slide 65
Etiology (cause)
Exposure to Aspergillus in a patient with asthma or cystic fibrosis Slide 65
Epidemiology (who)
Occurs almost exclusively with asthma or cystic fibrosis Slide 65
Risk Factors
Asthma; cystic fibrosis Slide 65
Pathology
Vigorous immunoglobulin E and G antibody response to Aspergillus fumigatus Slide 65
Clinical Manifestation
Acute asthma symptoms and exacerbations despite good control Slide 65
Diagnosis
Raised immunoglobulin E and G antibodies to Aspergillus fumigatus Slide 65
Treatment/Therapy
Not covered in the lecture
Mortality ★
Not covered in the lecture

Lecture 36 · Chronic Obstructive Pulmonary Disease

Lauren Reynolds, MSPA, PA-C · 1 conditions · source: 37. svCOPD 2026.pptx

Note: Built from the slides plus the lecture recording: the recording only chooses which facts to star, it adds no content. Both the 2020 four-group (A to D) and the 2023 and 2026 three-group (A, B, E) schemes are on the slides. Where the lecturer said any single exacerbation makes a patient high risk, the slides' definition (2 or more moderate, or 1 leading to hospitalization) is used. Brand names, device brands and dosing are left out.
Chronic obstructive pulmonary disease (COPD)★ Professor emphasized

★ The group (symptoms times risk) sets the treatment; know both the 2020 A to D and the current A, B, E schemes; spirometry confirms the diagnosis; the airflow grade, assessment test, dyspnea grade and BODE score are testable calculations.

Name of Condition
Chronic obstructive pulmonary disease (COPD) / chronic obstructive lung disease (COLD) Slides 1, 5
Definition
★ Persistent airflow obstruction plus respiratory symptoms caused by inhaled particulate exposure in the setting of genetic, developmental and social factors; an umbrella of chronic bronchitis and emphysema. Chronic bronchitis without airflow obstruction is not COPD Slides 5–7
Etiology (cause)
★ Tobacco smoke (about 90%); biomass burning (indoor cooking and heating, major in low- and middle-income countries); occupational coal dust, gold mining, welding, fumes; alpha-1 antitrypsin deficiency (about 3 to 4 per 10,000); sedentary lifestyle Slides 10–12, 19
Epidemiology (who)
About 6% of Americans; third leading cause of death worldwide (2023); underdiagnosis very common; symptoms begin in midlife Slides 8–9
Risk Factors
Smoking, biomass smoke, occupational exposures, alpha-1 antitrypsin deficiency (age 45 or under, nonsmoker, basilar emphysema, family history), inactivity Slides 10–12, 19
Pathology
Chronic inflammation, oxidative stress, protease-antiprotease imbalance. Chronic bronchitis subtype: airway narrowing and mucus plugging. Emphysema subtype: alveolar destruction and loss of elastic recoil; centrilobular upper-lobe in smokers, panlobular lower-lobe in alpha-1 antitrypsin deficiency. Air trapping and hyperinflation Slides 6–7, 11–15, 25
Clinical Manifestation
Progressive dyspnea (exertional dyspnea is the early sign), chronic cough, sputum, wheeze. Blue bloater (chronic bronchitis): sputum, rhonchi, cyanosis, edema. Pink puffer (emphysema): thin, pursed lips, barrel chest, distant breath sounds. Cor pulmonale, syncope, falls. Screen for heart disease, lung cancer, osteoporosis, depression, reflux, anemia Slides 14–22
Diagnosis
★ Spirometry before and after a bronchodilator: ratio below 0.70; response under 12% = irreversible. Airflow grade by 1-second volume: 1 at 80% or more, 2 at 50 to 79%, 3 at 30 to 49%, 4 below 30%. Assessment test 10 or more or dyspnea grade 2 or more = more symptoms. Low diffusing capacity = emphysema. Alpha-1 antitrypsin level below 11 micromol/L. Blood gas only in severe exacerbations Slides 23–31, 34–37
Treatment/Therapy
★ Group sets treatment: A one bronchodilator; B long-acting beta agonist plus antimuscarinic; E the same pair, add inhaled steroid if eosinophils 300 or more. Inhaled steroid never alone. Oral steroids for exacerbations only. Smoking cessation with counseling, pulmonary rehabilitation (B and E), yearly influenza and pneumococcal vaccines, albuterol rescue. Long-term oxygen for arterial oxygen under 55 mmHg or saturation below 88%. Exacerbation: bronchodilators, steroids, antibiotics if more and purulent sputum, noninvasive ventilation for hypercapnia. Older adults: spacer or soft mist devices, active rehabilitation referral, early palliative care Slides 38–51, 53–64
Mortality ★
BODE index (body mass index, obstruction, dyspnea, exercise) estimates 4-year survival: 0 to 2 points about 80%, 3 to 4 about 67%, 5 to 6 about 57%, 7 to 10 about 18%. Survival benefit: smoking cessation, long-term oxygen, noninvasive ventilation Slides 52, 63

Lecture 37 · Respiratory Infections and Vaccines

Robert Bobilin, MS, MPAS, PA-C (guest lecturer) · 12 conditions · source: 37. Respiratory Infections - Bobilin - 10-29-2026 SV.pptx

Note: Built from the slides plus the Zoom recording: the recording only chooses which facts to star, it adds no content. His study-focus slide (slides 127-128, posted with the revised deck on 31 October) is the exam guidance he promised: it names influenza vaccine product selection, respiratory syncytial virus eligibility and pneumococcal sequencing, superseding his in-lecture remark that vaccines need little detail. The example chest films will not be shown as 'what is it'. Brand names and dosing are left out.
Acute bronchitis★ Professor emphasized1 not covered

★ His theme: 'diagnostic restraint' - no routine antibiotics, whatever the sputum color or cough duration.

Name of Condition
Acute bronchitis Slides 14–15
Definition
A usually self-limited viral infection of the large airways; inflammation and mucus cause cough, sometimes with transient wheeze Slide 15
Etiology (cause)
Most uncomplicated episodes are viral; bacterial causes are uncommon. Consider pertussis with paroxysmal cough, post-tussive vomiting, whoop or exposure Slides 17–18
Epidemiology (who)
Follows cold-like symptoms; cough commonly lasts 2 to 3 weeks and may persist longer Slides 16–17
Risk Factors
A preceding viral upper respiratory infection; smoke and irritants worsen symptoms Slides 16, 19
Pathology
Inflammation and mucus in the large airways; wheeze depends on the severity of airflow limitation Slides 15–16
Clinical Manifestation
Low-grade fever, chills, aches, then cough with mucus, worst in the morning (★ green or yellow mucus does not mean bacteria); dyspnea, wheeze, chest tightness, throat tickle. Exam: central (substernal) wheeze, rhonchi that clear with cough, chest-wall tenderness; consolidation means think pneumonia Slides 16–17
Diagnosis
★ Clinical diagnosis; no routine complete blood count, sputum culture or chest film in uncomplicated cases (a blood count cannot tell viral from bacterial); image when vital signs, focal findings or risk suggest pneumonia; test for pertussis, influenza or COVID-19 when it changes care Slides 15, 17
Treatment/Therapy
★ No routine antibiotics (amoxicillin/clavulanate, clindamycin and fluoroquinolones are not default treatments); expectation setting, rest, fluids, avoiding smoke, acetaminophen (avoid duplicate acetaminophen in combination products); no routine opioid cough suppressants or corticosteroids; bronchodilator trial for selected wheezing patients; delayed 'pocket' prescription; return for dyspnea, hemoptysis, persistent fever, hypoxemia or worsening Slides 18–22
Mortality ★
Not covered in the lecture
Community-acquired pneumonia (bacterial)★ Professor emphasized

★ PSI is the preferred admission tool and CURB-65 is complementary; know the outpatient and inpatient regimens and when to withhold antibiotics.

Name of Condition
Community-acquired pneumonia (CAP) Slides 23, 25
Definition
Acute infection of the lung parenchyma and alveolar sacs, acquired outside the hospital or present early in admission; prior healthcare contact does not exclude it Slides 25, 27
Etiology (cause)
★ Streptococcus pneumoniae is the most common pathogen; Haemophilus influenzae, respiratory viruses; atypicals Mycoplasma pneumoniae, Chlamydophila pneumoniae and Legionella (cruises, hot tubs, fountains); Klebsiella, Moraxella, MRSA (methicillin-resistant Staphylococcus aureus), Pseudomonas Slides 24, 39–41
Epidemiology (who)
About 24.8 cases per 10,000 adults a year; highest incidence over 65; 15 to 20% hospitalized; influenza and pneumonia together are the 8th leading cause of death Slide 24
Risk Factors
Age (young children, older adults), immunocompromise, sick contacts, alcohol and smoking, aspiration, chronic obstructive pulmonary disease and heart disease Slides 28, 41
Pathology
Stages: congestion, red hepatization, gray hepatization, resolution (not hard rules) Slide 26
Clinical Manifestation
Higher fevers and chills, pleuritic or stabbing chest pain, productive possibly purulent cough, dyspnea and tachypnea; sepsis signs when systemic. Exam: crackles or diminished sounds over one lobe, dullness, egophony (E to A), whispered pectoriloquy, increased tactile fremitus, pleural rub Slides 23, 27–28
Diagnosis
★ Chest radiograph (lung ultrasound with expertise); oxygen saturation, vital signs, organ function, sepsis risk; ★ Pneumonia Severity Index plus judgment for admission; CURB-65 complementary (0 to 1 home, 2 hospital, 3 to 5 high severity); cultures only for severe disease, resistance risk or failure; computed tomography for uncertainty or cavitation Slides 29–31, 33, 37, 45
Treatment/Therapy
Outpatient, healthy: amoxicillin or doxycycline (macrolide alone only if pneumococcal resistance below 25%). Outpatient with comorbidities: amoxicillin/clavulanate, cefpodoxime or cefuroxime plus azithromycin or doxycycline, or a respiratory fluoroquinolone. Inpatient nonsevere: beta-lactam plus macrolide, or a fluoroquinolone alone. Severe: beta-lactam plus azithromycin or a fluoroquinolone. Minimum 3 days (nonsevere), at least 5 days (severe). No routine steroids in nonsevere disease Slides 38, 40, 43–45, 47
Mortality ★
CURB-65 risk of death: under 3% (0 to 1), 9% (2), 15 to 40% (3 to 5). Pneumonia Severity Index class mortality: I 0.1%, II 0.6%, III 0.9%, intravenous 9.3%, V 27.0% Slides 30–31
Hospital-acquired and ventilator-associated pneumonia1 not covered
Name of Condition
Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) Slide 25
Definition
HAP develops 48 hours or more after admission and was not incubating on admission; VAP develops more than 48 hours after endotracheal intubation Slide 25
Etiology (cause)
Staphylococcus aureus and gram-negative bacilli including Pseudomonas and Enterobacterales; VAP more likely Pseudomonas or multidrug-resistant organisms Slides 39, 48
Epidemiology (who)
Not covered in the lecture
Risk Factors
Ventilator circuits contaminated by flora, secretions, hands of healthcare workers, circuit changes, tube biofilm, prior antibiotics Slide 48
Pathology
Colonized secretions are inhaled into the lungs through the endotracheal tube Slide 48
Clinical Manifestation
A new pneumonia during admission or ventilation Slide 25
Diagnosis
Respiratory cultures; local antibiogram, prior cultures and recent antibiotics; early or late timing alone does not select the regimen Slides 39, 42, 46
Treatment/Therapy
Antipseudomonal beta-lactam with methicillin-sensitive staphylococcal coverage (piperacillin/tazobactam or cefepime); add vancomycin or linezolid for methicillin-resistant S. aureus risk; a second antipseudomonal class for selected high-risk patients; de-escalate; usually 7 days. VAP prevention: early extubation, hand washing, sterile technique, fewer circuit changes, head of bed elevated, secretion drainage and mouth care Slides 42, 46, 49
Mortality ★
VAP: higher mortality and prolonged intensive care stay Slide 48
Aspiration pneumonia (and pneumonitis)1 not covered
Name of Condition
Aspiration pneumonia versus aspiration pneumonitis Slides 50–51
Definition
Aspiration pneumonia: bacterial infection after aspiration of colonized oropharyngeal material. Pneumonitis: sterile chemical injury, often after gastric aspiration Slides 50–51
Etiology (cause)
Anaerobic oral flora and varied organisms; pneumonitis is chemical, not infectious Slides 28, 41
Epidemiology (who)
Can occur in community or hospital settings; elderly patients with dysphagia Slides 25, 50
Risk Factors
Dysphagia, altered consciousness, impaired airway protection (stroke, seizure) Slide 50
Pathology
Gravity-dependent airspace opacity in a lobar or segmental distribution Slide 33
Clinical Manifestation
Pneumonitis: abrupt respiratory decline after a witnessed aspiration, fever or leukocytosis possible without infection. Pneumonia: infectious syndrome with an infiltrate; the event may be unwitnessed Slide 51
Diagnosis
Chest film showing a gravity-dependent opacity; reassess persistence for secondary infection or complication Slides 33, 51
Treatment/Therapy
Pneumonitis: support oxygenation and airway, no prophylactic antibiotics. Pneumonia: the community- or hospital-acquired pneumonia regimen by setting and severity; ★ anaerobic coverage only for abscess or empyema; assess swallowing, oral hygiene, positioning Slides 50–51, 126
Mortality ★
Not covered in the lecture
Lung abscess2 not covered
Name of Condition
Lung abscess Slide 53
Definition
A cavitating lung infection, often after aspiration, that can become chronic Slide 53
Etiology (cause)
Anaerobic oral flora, Mycobacterium tuberculosis, nontuberculous mycobacteria, Staphylococcus aureus including methicillin-resistant strains Slide 41
Epidemiology (who)
Not covered in the lecture
Risk Factors
Aspiration Slide 53
Pathology
Infection grows and cavitates, damaging tissue; cavity with an air-fluid level Slides 53–54
Clinical Manifestation
Insidious, prolonged (weeks): fever, chills, sweats, cough, purulent foul-smelling sputum, hemoptysis, pleuritic pain, dyspnea, malaise; dullness, whispered pectoriloquy, bronchophony, amphoric breath sounds (like breathing across an open jar) Slide 53
Diagnosis
★ Cavitary lesion with an air-fluid level on chest film and computed tomography; bronchoscopy for obstruction, unusual pathogens or failure to improve Slides 54, 56
Treatment/Therapy
Usually begins with antibiotics: intravenous ampicillin/sulbactam then oral amoxicillin/clavulanate, for several weeks; clindamycin reserved (C. difficile risk); pulmonary or infectious disease review for drainage or surgery if large or refractory; chest physiotherapy not essential Slides 38, 56
Mortality ★
Not covered in the lecture
Pneumocystis jirovecii pneumonia★ Professor emphasized

★ Know the presentation in HIV, the workup ladder (induced sputum, then lavage), TMP-SMX, the steroid trigger (arterial oxygen below 70) and the prophylaxis threshold.

Name of Condition
Pneumocystis jirovecii pneumonia (PJP), formerly Pneumocystis carinii pneumonia (PCP) Slide 58
Definition
A fungal pneumonia, the most common opportunistic infection in people with HIV (human immunodeficiency virus); treated primarily with antibiotics Slide 58
Etiology (cause)
Pneumocystis jirovecii Slide 58
Epidemiology (who)
Falling with prophylaxis and antiretroviral therapy; mortality 10 to 20%; still a major cause of death in acquired immunodeficiency syndrome in the United States Slides 59–60
Risk Factors
HIV (human immunodeficiency virus); chemotherapy, anti-rejection drugs, long-term steroids, organ transplant, blood cancer Slide 61
Pathology
Interstitial pneumonia Slides 33, 70
Clinical Manifestation
★ Progressive exertional dyspnea (95%) and nonproductive cough (95%), fever (over 80%), chest discomfort, weight loss, chills; tachypnea, tachycardia, mild crackles, but up to half have a normal exam Slides 62–63
Diagnosis
Induced sputum or bronchoalveolar lavage microscopy or polymerase chain reaction (a negative induced sputum does not exclude; go to lavage); beta-D-glucan supports but is not specific; lactate dehydrogenase nonspecific; HIV (human immunodeficiency virus) test, CD4 (cluster of differentiation 4) count and viral load; film: diffuse bilateral perihilar infiltrates; start therapy while confirming if suspicion is high Slides 65–70
Treatment/Therapy
★ Trimethoprim-sulfamethoxazole preferred (21 days in HIV); alternatives clindamycin plus primaquine, intravenous pentamidine, atovaquone (mild); check G6PD (glucose-6-phosphate dehydrogenase) before primaquine or dapsone; ★ steroids if room-air arterial oxygen below 70 mm Hg; prophylaxis for CD4 below 100 (or 100 to 200 with detectable HIV (human immunodeficiency virus) RNA); antiretroviral therapy within about 2 weeks Slides 71–73
Mortality ★
10 to 20% Slide 60
Histoplasmosis★ Professor emphasized1 not covered

★ He said it is 'going to show up on your PANCE'.

Name of Condition
Histoplasmosis Slide 75
Definition
Infection by the fungus Histoplasma capsulatum Slide 75
Etiology (cause)
Inhaled from soil and bird or bat droppings (farming, gardening, chicken coops) Slide 75
Epidemiology (who)
United States: mainly central and eastern states, especially the Ohio and Mississippi River valleys; rare Slide 75
Risk Factors
Soil disruption, bird or bat droppings; late HIV Slides 41, 75
Pathology
Granuloma (some patients show only a granuloma on film) Slide 76
Clinical Manifestation
High fever, chills, myalgias, nonproductive cough, chest pain, headache 3 to 17 days after exposure; some asymptomatic Slide 76
Diagnosis
Ask about geography, soil and droppings; ★ urine Histoplasma antigen, often with serum antigen and antibody; early negative tests do not exclude; cross-reacts with Blastomyces; culture or histopathology for severe or uncertain cases Slide 77
Treatment/Therapy
Mild acute disease in an immunocompetent adult: often observation; itraconazole for prolonged or progressive illness or higher-risk hosts; specialist-led amphotericin induction for severe or disseminated disease; chronic cavitary disease: azole for at least 12 months Slide 78
Mortality ★
Not covered in the lecture
Cryptococcosis1 not covered
Name of Condition
Cryptococcosis Slide 123
Definition
Infection by Cryptococcus neoformans or C. gattii after environmental inhalation Slide 123
Etiology (cause)
Cryptococcus neoformans, C. gattii Slide 123
Epidemiology (who)
Also occurs without immunocompromise Slide 123
Risk Factors
HIV, transplant, steroids Slide 123
Pathology
Nodules or consolidation Slide 123
Clinical Manifestation
Cough, fever; can mimic community-acquired pneumonia, tuberculosis or cancer; headache or confusion suggests central nervous system involvement Slide 123
Diagnosis
Serum cryptococcal antigen, respiratory culture or histology; evaluate for central nervous system or disseminated disease, often with a lumbar puncture Slide 123
Treatment/Therapy
Mild isolated pulmonary: fluconazole, generally 6 to 12 months. Severe, central nervous system or disseminated: liposomal amphotericin B plus flucytosine induction, then fluconazole; infectious disease consultation; monitor toxicity; counsel adherence Slide 123
Mortality ★
Not covered in the lecture
Psittacosis★ Professor emphasized1 not covered

★ 'A super common medical boards question', though not common enough to deserve a lot of attention.

Name of Condition
Psittacosis (parrot fever) Slide 80
Definition
Infection by the obligate intracellular bacterium Chlamydia psittaci Slide 80
Etiology (cause)
Chlamydia psittaci from parrots, parakeets, canaries and other birds Slides 80–81
Epidemiology (who)
Rare, about 200 patients a year; an occupational disease (zoo and pet-shop workers, poultry farmers, ranchers) Slides 80–81
Risk Factors
Handling sick birds, mouth-to-beak resuscitation; human-to-human spread rare Slide 81
Pathology
Stages: flulike illness with a normal film, mild to moderate pneumonia, severe pneumonia, respiratory failure and septic shock Slide 84
Clinical Manifestation
Fever and cough (50 to 90%, cough usually dry), chills, malaise, dyspnea, sore throat, epistaxis, severe headache, photophobia; ★ relative bradycardia, splenomegaly, Horder spots (rose-spot-like macules on the face), hemolytic anemia Slides 82–83
Diagnosis
Ask about bird exposure; ★ respiratory nucleic acid amplification test or polymerase chain reaction; paired serology cross-reacts; routine culture does not detect it; film: unilateral lower-lobe dense infiltrate, resolving in about 6 weeks Slides 85–86
Treatment/Therapy
★ Doxycycline, promptly, 10 to 14 days after fever resolves; macrolide with infectious disease input if tetracyclines are unsuitable; standard precautions; report to public health; veterinary assessment of birds Slides 87–88
Mortality ★
Not covered in the lecture
Mycoplasma pneumoniae pneumonia2 not covered
Name of Condition
Mycoplasma pneumoniae pneumonia Slide 89
Definition
An atypical pneumonia caused by Mycoplasma pneumoniae, an organism that lacks a cell wall Slide 89
Etiology (cause)
Mycoplasma pneumoniae Slide 89
Epidemiology (who)
School-age children and young adults; household or group outbreaks Slide 89
Risk Factors
Outbreak exposure; alcohol and smoking Slide 28
Pathology
Not covered in the lecture
Clinical Manifestation
Gradual fever, persistent cough, headache, variable chest findings; severe or extrapulmonary illness can occur Slide 89
Diagnosis
Respiratory nucleic acid amplification test when results change care Slide 89
Treatment/Therapy
Macrolide or doxycycline (respiratory fluoroquinolone an alternative); ★ beta-lactams are ineffective: no cell wall; doxycycline after macrolide failure; no vaccine Slide 89
Mortality ★
Not covered in the lecture
Influenza★ Professor emphasized

★ Treat high-risk patients promptly, even after 48 hours; know who avoids which antiviral.

Name of Condition
Influenza Slide 91
Definition
A highly contagious airborne orthomyxovirus infection Slide 91
Etiology (cause)
Influenza A (more pathogenic, most human infections), B and C; subtypes by hemagglutinin and neuraminidase; antigenic drift and shift Slides 92–94
Epidemiology (who)
Fall and winter epidemics, peaking in mid-February; incubation 1 to 4 days Slides 95–96
Risk Factors
Severe disease: under 5, 65 and older, long-term care, immunocompromise, chronic organ disease, pregnancy and 2 weeks postpartum, severe obesity Slides 97–98
Pathology
Influenza pneumonia: primary viral or secondary bacterial (pneumococcal or staphylococcal) Slide 106
Clinical Manifestation
Sudden onset: fever 100 to 104 F, cough, sore throat, myalgias, frontal or retro-orbital headache, severe fatigue, red watery eyes, diarrhea in children; wheezes or rhonchi, tachycardia, dry skin Slides 99–102
Diagnosis
★ Rapid molecular assay or reverse-transcription polymerase chain reaction; a negative rapid antigen test does not exclude; do not wait for results in hospitalized or high-risk patients; chest film to rule out pneumonia in the elderly or high-risk Slides 95, 104–106
Treatment/Therapy
★ Oseltamivir preferred (hospitalized, severe, high-risk, pregnancy), even after 48 hours; baloxavir single dose within 48 hours but not in pregnancy, breastfeeding, severe immunosuppression or hospitalized patients; avoid inhaled zanamivir in asthma or chronic obstructive pulmonary disease; amantadine and rimantadine not recommended; avoid aspirin under 18 (Reye syndrome); annual vaccination Slides 4–6, 107–110
Mortality ★
3 to 5 million cases and 250,000 to 500,000 deaths worldwide a year (context only) Slide 96
COVID-19★ Professor emphasized2 not covered

★ Stratify severity first; oxygenation decides the pathway.

Name of Condition
Coronavirus disease 2019 (COVID-19) Slides 111–112
Definition
Disease caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), from asymptomatic infection to respiratory failure Slide 112
Etiology (cause)
The virus, spread mainly by inhaling infectious respiratory particles, especially indoors with poor ventilation Slide 112
Epidemiology (who)
Median incubation about 5 days; 18 to 33% asymptomatic Slide 114
Risk Factors
Age (risk rises substantially above 65), immunocompromise, multiple chronic conditions, lack of current vaccination Slide 113
Pathology
Not covered in the lecture
Clinical Manifestation
Cough, shortness of breath, fever, myalgia, headache; less often sore throat, anosmia, dysgeusia, anorexia, nausea or diarrhea Slides 114–115
Diagnosis
★ Nucleic acid amplification test (including polymerase chain reaction) most sensitive; repeat a negative antigen test after 48 hours (2 tests if symptomatic, 3 if not); imaging for pneumonia and complications; D-dimer alone does not diagnose thrombosis. Severity: mild (no dyspnea, normal film), moderate (abnormal film, saturation 94% or more), severe (below 94%, infiltrates over 50%), critical Slides 117, 119
Treatment/Therapy
High-risk outpatients without hypoxemia: nirmatrelvir/ritonavir within 5 days (check interactions, renal dosing, hepatic contraindications) or 3-day remdesivir within 7 days; molnupiravir only if these are unsuitable, avoid in pregnancy; no steroids without hypoxemia. Hypoxemic inpatients: dexamethasone, consider remdesivir, baricitinib or tocilizumab for rapid progression, thromboprophylaxis Slides 120–122
Mortality ★
Not covered in the lecture

Lecture 38 · Mycobacterial Infections, Including Tuberculosis

Robert Bobilin, MS, MPAS, PA-C, Emeritus (guest lecturer) · 3 conditions · source: 38. Mycobacterial Infections including Tuberculosis - Bobilin - 10-29-2025 SV.pptx

Note: Built from the slides plus the Zoom recording, which only chooses which facts to star. Where the lecturer called fever and night sweats 'pathognomonic', the slide (a list of manifestations) is followed. Epidemiology figures are context only. Dosing is left out.
Tuberculosis (pulmonary and extrapulmonary)★ Professor emphasized

★ Infection versus disease decides infectiousness, evaluation and treatment; know the 5, 10 and 15 mm cut-offs, 3 sputum specimens, isolation and notification, and the 2 + 4 month regimen.

Name of Condition
Tuberculosis (TB) disease Slide 5
Definition
A chronic granulomatous disease caused by Mycobacterium tuberculosis, usually of the lung but able to reach any organ by hematogenous spread Slide 12
Etiology (cause)
Mycobacterium tuberculosis complex (M. tuberculosis the principal human pathogen; also M. bovis, M. africanum): acid-fast bacilli with lipid-rich, mycolic-acid walls; slow growing Slides 4–5
Epidemiology (who)
Leading cause of death from a single infectious agent worldwide; about a quarter of the world infected; in the United States most cases occur in people born outside the country Slides 6–7
Risk Factors
Exposure: close contact, enclosed poorly ventilated spaces, settings with ongoing transmission, high-incidence areas. ★ Progression: HIV or major immunosuppression, tumor necrosis factor inhibitors, transplant, prolonged steroids, infection within 2 years, infancy and young childhood; also diabetes, chronic kidney disease or dialysis, silicosis, low weight, tobacco and alcohol Slides 14–15
Pathology
Primary infection contained, or progressive primary disease when containment fails; latent foci reactivate with impaired immunity (secondary tuberculosis); caseation, cavities, miliary dissemination Slides 9–10, 12
Clinical Manifestation
Persistent cough, hemoptysis or pleuritic pain, fever and night sweats, weight loss, fatigue; may be mild or absent; exam has limited sensitivity and a normal exam does not exclude it. Extrapulmonary: painless lymph node enlargement, pleural effusion, central nervous system (headache, altered mental status), spine (back pain, vertebral destruction), disseminated disease Slides 8, 16–17
Diagnosis
Tuberculin skin test or interferon-gamma release assay shows infection only. ★ 3 sputum specimens 8 to 24 hours apart (one early morning): smear, culture, a rapid molecular test, susceptibility testing; HIV test; chest film (upper-lobe cavities after primary, hilar adenopathy in primary, miliary nodules); imaging cannot confirm Slides 19–29
Treatment/Therapy
★ Notify the tuberculosis program; airborne isolation room; N95; source control; end isolation by criteria. 2 months of isoniazid, rifampin, pyrazinamide and ethambutol, then 4 months of isoniazid and rifampin (ethambutol stops once susceptibility is known), daily directly observed therapy; 17-week rifapentine-moxifloxacin regimen from age 12; rifampin resistance needs expert management; monthly monitoring for liver injury, interactions, toxicity Slides 33–36
Mortality ★
Preventable and curable; post-tuberculosis bronchiectasis and scarring possible Slides 6, 29
Latent tuberculosis infection★ Professor emphasized1 not covered

★ Asymptomatic and not infectious; exclude disease before treating; know the 5, 10 and 15 mm skin test cut-offs.

Name of Condition
Latent tuberculosis infection (LTBI) Slide 10
Definition
Infection with Mycobacterium tuberculosis without disease: asymptomatic, not infectious, no evidence of disease after clinical evaluation Slide 10
Etiology (cause)
Mycobacterium tuberculosis contained by the immune system Slides 10, 12
Epidemiology (who)
About a quarter of the world's population has been infected Slide 6
Risk Factors
Exposure risk; reactivation risk with impaired immunity Slides 14–15
Pathology
Foci can harbor viable organisms for years and reactivate when immunity falls Slide 12
Clinical Manifestation
None; chest film usually normal Slides 10, 29
Diagnosis
★ Tuberculin skin test thresholds: 5 mm (HIV, recent close contact, transplant, major immunosuppression, imaging of prior tuberculosis), 10 mm (exposure or medical risk, congregate settings, children under 5), 15 mm (no risk factors); measure induration, not erythema, at 48 to 72 hours; the interferon-gamma release assay is preferred after BCG (bacille Calmette-Guerin) vaccination; repeat 8 to 10 weeks after exposure if early tests are negative; neither test separates latent infection from disease Slides 19–25
Treatment/Therapy
Exclude disease first; 3HP (weekly isoniazid plus rifapentine for 3 months), 4R (daily rifampin for 4 months) or 3HR (daily isoniazid plus rifampin for 3 months); 6H or 9H when rifamycins are unsuitable; check interactions, pregnancy and source-case resistance Slide 37
Mortality ★
Not covered in the lecture
Nontuberculous mycobacterial lung disease1 not covered
Name of Condition
Nontuberculous mycobacterial (NTM) lung disease (atypical mycobacterial disease) Slide 38
Definition
Pulmonary or extrapulmonary disease from environmental mycobacteria; a respiratory isolate alone does not prove disease Slide 38
Etiology (cause)
Mycobacterium avium complex (MAC, a common cause), M. kansasii, M. abscessus Slides 5, 38
Epidemiology (who)
Most infections come from environmental exposure; person-to-person spread uncommon Slide 38
Risk Factors
Bronchiectasis, chronic obstructive pulmonary disease, immune dysfunction Slide 38
Pathology
Nodular bronchiectasis or fibrocavitary disease Slide 39
Clinical Manifestation
Chronic cough and sputum, fatigue, weight loss, reduced appetite, dyspnea or hemoptysis Slide 39
Diagnosis
★ All domains: compatible symptoms and imaging, alternatives excluded, usually 2 or more sputum cultures of the same species (or one bronchial wash or lavage or a qualifying biopsy); an acid-fast smear cannot tell nontuberculous mycobacteria from tuberculosis Slides 4, 39
Treatment/Therapy
Macrolide-susceptible MAC (specialist-directed): azithromycin, ethambutol and a rifamycin, at least 12 months after culture conversion; cavitary or severe: daily therapy and initial intravenous amikacin; persistent positive cultures after 6 months or more: inhaled liposomal amikacin; other species susceptibility-guided Slide 40
Mortality ★
Not covered in the lecture